FAQ

sarpogrelate

Known as: 2-(dimethylamino)-1-((2-(3-methoxyphenyl)phenoxy)methyl)ethyl hydrogensuccinate hydrochloride, mono-(2-(dimethylamino)-1-((2-(2-(3-methoxyphenyl)ethyl)phenoxy)methyl)ethyl)succinate hydrochloride 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1994-2018
05101519942018

Related topics

Related topics

5 relations

Broader (4)

Fibrinolytic AgentsPlatelet Aggregation InhibitorsSerotonin AntagonistsSuccinates

Narrower (1)

MCI 9042

Related mentions per year

Related mentions per year

1937-2018
19401960198020002020
sarpogrelate
Fibrinolytic Agents
Succinates
Serotonin Antagonists
Platelet Aggregation Inhibitors
MCI 9042

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Mechanism of sarpogrelate action in improving cardiac function in diabetes.
Although sarpogrelate, a 5-HT(2A) receptor antagonist, has been reported to exert beneficial effects in diabetes, the mechanisms… (More)
Is this relevant?
2009
2009
Sarpogrelate hydrochloride reduced intimal hyperplasia in experimental rabbit vein graft.
OBJECTIVES The selective 5-HT(2A) receptor antagonist sarpogrelate has been clinically used for treatment in atherosclerotic… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial.
BACKGROUND AND PURPOSE The antiplatelet agent sarpogrelate is a selective inhibitor of 5-hydroxytryptamine receptors. The purpose… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2007
2007
Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease.
Peripheral arterial disease (PAD) is 1 of the major manifestations of atherosclerosis. PAD is associated with endothelial… (More)
Is this relevant?
2003
2003
Sarpogrelate treatment reduces restenosis after coronary stenting.
BACKGROUND Sarpogrelate, a serotonin blocker, has been reported to inhibit the serotonin-induced proliferation of rat aortic… (More)
Is this relevant?
2003
2003
Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism.
Although sarpogrelate HCl is widely used for the prevention of arterial thrombosis, its effect on atherosclerosis is unknown… (More)
Is this relevant?
2002
2002
Sarpogrelate, a specific 5HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease.
BACKGROUND Serotonin (5-hydroxytryptamine: 5-HT) reduces the coronary blood flow (CBF) as a product of aggregating platelets… (More)
Is this relevant?
2002
2002
The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts.
OBJECTIVE We aimed to clarify the relation between sarpogrelate (SG), a 5-hydroxytryptamine (5-HT)-2 receptor blocker, and… (More)
Is this relevant?
2001
2001
Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans.
To evaluate the effects of the 5-HT2 receptor antagonist sarpogrelate hydrochloride (sarpogrelate) on platelet responses in… (More)
Is this relevant?
2000
2000
The effects of sarpogrelate on cardiomyocyte hypertrophy.
Sarpogrelate was developed as an antiplatelet agent antagonizing 5-hydroxytryptamine (5-HT) receptors. It had been reported that… (More)
Is this relevant?